Clinical trial · Observational
Effect of Aromatherapy on the Management of Chemotherapy-Induced Neuropathy (CIN)
Effect of Aromatherapy on the Management of Chemotherapy-Induced Neuropathy (CIN) in Patients Receiving Taxane Therapy for Breast Cancer.
NCT07779135CI-TRIAL-00123231AROMA NEUROTAXrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to describe the effect of an essential oil-based blend applied topically in the management of painful symptoms, sensory disturbances, or functional impairment caused by Chemotherapy-Induced Neuropathy (CIN) in breast cancer patients who have undergone paclitaxel treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Neuropathic Pain in Cancer | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sensory and pain-related symptoms evolution measured with CIPN20
- timeFrame
- At enrollment, Day 7 and Day 30 follow-up
- description
- The CIPN20 (Chemotherapy-Induced Peripheral Neuropathy) questionnaire is a 20-item questionnaire used to assess and monitor symptoms, specifically targeting chemotherapy-induced neuropathies. We will limit ourselves to items 31 through 44, which concern sensory and pain-related symptoms. Items 31-36, 39, and 40 address sensory symptoms and problems. Items 37, 38, 41-44 address motor symptoms and problems. The individual items should be scored such that higher scores represent more symptoms/problems (i.e., higher score = worse).
Secondary outcomes (4)
- measure
- Quality of life measured with EORTC QLQ C30
- timeFrame
- At enrollment, Day 7 and Day 30 follow-up
- description
- The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with breast cancer * who have painful or bothersome CIN * occurring in the context of paclitaxel treatment (during or after treatment) * for whom conventional drug treatments provide insufficient relief (or are poorly tolerated or refused). * Age ≥ 18 years * Who, after receiving information, do not object to the use of their data for the purposes of this research Exclusion Criteria: * Pre-existing neuropathy (e.g., due to diabetes) * Known allergy to an essential oil or a component of essential oils (e.g., linalool) * Presence of wounds on the affected areas * Refusal to use aromatherapy * Inability to complete the questionnaires
References
Publications (0)
Data not yet available
No reference posted for this study.